New drug under observation for rare genetic disorder

NCT ID NCT07450664

ENROLLING_BY_INVITATION Disease control Sponsor: Soleno Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers will track side effects and how the drug affects their health over time. The goal is to gather more safety information, not to test if the drug cures the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Prader-Willi syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRADER-WILLI SYNDROME

Contacts and locations

Locations

Neurocrine Clinical Site

Phoenix, Arizona, 85016, United States
Neurocrine Clinical Site

Los Angeles, California, 90027, United States
Neurocrine Clinical Site

Sacramento, California, 95821, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Atlanta, Georgia, 30322, United States
Neurocrine Clinical Site

Chicago, Illinois, 60611, United States
Neurocrine Clinical Site

Indianapolis, Indiana, 46202, United States
Neurocrine Clinical Site

Boston, Massachusetts, 02115, United States
Neurocrine Clinical Site

Ann Arbor, Michigan, 48109, United States
Neurocrine Clinical Site

Lansing, Michigan, 48912, United States
Neurocrine Clinical Site

Minneapolis, Minnesota, 55454, United States
Neurocrine Clinical Site

Rochester, Minnesota, 55905, United States
Neurocrine Clinical Site

Saint Paul, Minnesota, 55102, United States
Neurocrine Clinical Site

Kansas City, Missouri, 64111, United States
Neurocrine Clinical Site

Paterson, New Jersey, 07503, United States
Neurocrine Clinical Site

Valley Stream, New York, 11580, United States
Neurocrine Clinical Site

Chapel Hill, North Carolina, 27514, United States
Neurocrine Clinical Site

Durham, North Carolina, 27710, United States
Neurocrine Clinical Site

Portland, Oregon, 97227, United States
Neurocrine Clinical Site

Nashville, Tennessee, 37232, United States
Neurocrine Clinical Site

Dallas, Texas, 75231, United States
Neurocrine Clinical Site

Houston, Texas, 77030, United States
Neurocrine Clinical Site

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.